Amgen cuts lupus programs for futility, hours after Lilly officially walks away from one too

In a day chock-full of Big Pharma earning calls and accompanying pipeline culls, Amgen is no exception, slicing both of its mid-stage lupus programs for futility. The decision came hours after Lilly did the same for a Nektar Therapeutics-partnered asset.